Oral liquid medicine innovation

We invest heavily in research, development, and technological advancements. With state-of the-art facilities in both the UK and Greece, we can create new, effective solutions for patients with swallowing difficulties, as well as assess the latest developments in the global market.

By listening to our customers, we respond to their needs through a continual programme of new product development. Our medicines are developed to ensure they contain minimal excipients, making many of them suitable for patients of all ages, with a variety of religious and dietary requirements. All our products comply with safe excipient level guidelines, reassuring our patients and healthcare professionals of their quality.

Manufacturing solutions

Rosemont are committed to the pursuit of excellence in everything that we do, always striving to uphold the highest quality standards. We adhere to Good Manufacturing Practice (GMP) and International Conference on Harmonisation (ICH) Q10 quality control guidelines.  

Our manufacturing facilities are also regularly inspected by both the UK and US pharmaceutical regulatory agencies. Additional inspections come from the many healthcare institutions, customers and companies purchasing Rosemont oral liquid medicines worldwide. 

Alongside this, Rosemont has invested a seven-figure sum into a new Innovation Centre development in the UK. The aim of the facility is to increase liquid medicine output globally, develop new products suitable for multiple markets, and enhance company growth. 

Rosemont’s scientific teams in the UK and Greece are continually researching and developing new effective solutions for patients with swallowing difficulties, to ensure we are at the forefront of technological advancements.